RUTW241108P2515000
- 0.00
- 0.000.00%
Russell 2000 Index Newsroom
The "most lethal in history" nomination of the usa Secretary of Health! Vaccine stocks have been plummeting for consecutive days, and Kennedy has been criticized as the number one threat to public health.
On Friday, biontech once fell nearly 9%, moderna fell over 7%, and nasdaq biotechnology index dropped over 4%. Industry insiders said that Kennedy's 'junk science' poses a huge threat to public health.
Biden Pushes Ahead With Methane Fee Despite Trump's Win, Asks E.U. to Align With U.S.
Vizio Gains on Report About Walmart Integration Plans
Madrigal Pharmaceuticals Gains Amid Takeover Speculation
Alphatec Files to Sell 1.13M Shares of Common Stocks by Selling Shareholders
Gladstone Commercial Corporation Announces Retirement Of COO Terry Lee Brubaker, Effective December 2, 2024; Michael LiCalsi, The Co's General Counsel And Secretary, Who Also Serves As Gladstone Administration's President, General Counsel And...
Gladstone Land Announces Retirement Of COO Terry Lee Brubaker
Perspective Therapeutics To Discuss Data On [212Pb]VMT-α-NET Presented At The 2024 NANETS Multidisciplinary NET Medical Symposium On November 21, 2024
12 Consumer Discretionary Stocks Moving In Friday's Pre-Market Session
12 Industrials Stocks Moving In Friday's Pre-Market Session
Watching Madrigal Pharmaceuticals; Traders Circulate Unconfirmed Rumor From M&A Blog That The Co May Be Seeing Takeover Interest
Life Sciences Stocks Viewed Positively at TD Cowen Despite Post-election Weakness
Shares Of IRobot See Volume, Popular Account On X Announces They Bought The Stock
Crescent Energy Company Goes Ex Dividend Monday
A Look Into AeroVironment Inc's Price Over Earnings
Regenxbio Down 13% Ahead of Data Readout for Muscular Dystrophy Asset
SolarEdge, Maxeon Solar Slammed as Morgan Stanley Cuts to Sell Equivalent
Analyst Expectations For Independence Realty Trust's Future
Catalyst Watch: Nvidia Earnings, Microsoft Ignite, Crypto Confidence, and P&G Event
HC Wainwright & Co. Reiterates Buy on Compass Therapeutics, Maintains $10 Price Target